Drug Overview
Tagrisso (osimertinib) is a third-generation epidermal growth factor receptor (EGFR) inhibitor developed by AstraZeneca. Tagrisso has shown clinical activity against the EGFR T790M mutation, which is estimated to be responsible for over half of all cases of resistance to early-generation EGFR tyrosine kinase inhibitors. As a result, Tagrisso not only inhibits tumor growth and induces cell death in previously treated patients with T790M mutation, but the drug may also be a therapeutic option for first-line EGFR-positive patients to prevent de novo resistance due to the T790M mutation. Tagrisso is also more tolerable than early-generation EGFR inhibitors, due to its ability to spare wild-type EGFR, further enhancing its potential as a first-line therapy.
Tagrisso (osimertinib) is a third-generation epidermal growth factor receptor (EGFR) inhibitor developed by AstraZeneca. Tagrisso has shown clinical activity against the EGFR T790M mutation, which is estimated to be responsible for over half of all cases of resistance to early-generation EGFR tyrosine kinase inhibitors. As a result, Tagrisso not only inhibits tumor growth and induces cell death in previously treated patients with T790M mutation, but the drug may also be a therapeutic option for first-line EGFR-positive patients to prevent de novo resistance due to the T790M mutation. Tagrisso is also more tolerable than early-generation EGFR inhibitors, due to its ability to spare wild-type EGFR, further enhancing its potential as a first-line therapy.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
